{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAP-IT&page=6", "query": { "intervention": "CAP-IT", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 326, "total_pages": 33, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAP-IT&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAP-IT&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T18:19:48.511Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03308942", "title": "Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "TSR-042 (Dostarlimab)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2017-09-29", "completion_date": "2021-08-31", "has_results": true, "last_update_posted_date": "2023-10-16", "last_synced_at": "2026-11-04T18:19:48.511Z", "location_count": 16, "location_summary": "Whittier, Alaska • Port Saint Lucie, Florida • Atlanta, Georgia + 13 more", "locations": [ { "city": "Whittier", "state": "Alaska" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Harvey", "state": "Illinois" }, { "city": "Tinley Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03308942" }, { "nct_id": "NCT03486873", "title": "Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Solid Tumors", "Hematologic Malignancies" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Standard of Care (SOC)", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "MK-4280", "type": "DRUG" }, { "name": "MK-4280A", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (+) Berahyaluronidase alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3500, "start_date": "2018-08-21", "completion_date": "2043-08-04", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-11-04T18:19:48.511Z", "location_count": 65, "location_summary": "Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03486873" }, { "nct_id": "NCT02531308", "title": "Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-07", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-11-04T18:19:48.511Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02531308" }, { "nct_id": "NCT04939415", "title": "RCT of Modified Qing Fei Pai Du Tang (mQFPD) for COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "mQFPD", "type": "DRUG" }, { "name": "organic brown rice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2021-07-01", "completion_date": "2022-03-13", "has_results": true, "last_update_posted_date": "2025-09-05", "last_synced_at": "2026-11-04T18:19:48.511Z", "location_count": 2, "location_summary": "Los Angeles, California • San Diego, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04939415" }, { "nct_id": "NCT04177680", "title": "Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypertriglyceridemia" ], "interventions": [ { "name": "Omega 3 pentaenoic acid", "type": "DRUG" }, { "name": "icosapent ethyl", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Matinas BioPharma Nanotechnologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2020-06-03", "completion_date": "2021-01-18", "has_results": true, "last_update_posted_date": "2022-03-04", "last_synced_at": "2026-11-04T18:19:48.511Z", "location_count": 8, "location_summary": "Jacksonville, Florida • Jupiter, Florida • Port Saint Lucie, Florida + 5 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Addison", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04177680" }, { "nct_id": "NCT01406873", "title": "Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myotonic Dystrophy" ], "interventions": [ { "name": "Mexiletine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Rochester", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 42, "start_date": "2011-06", "completion_date": "2017-03", "has_results": true, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-11-04T18:19:48.511Z", "location_count": 1, "location_summary": "Rochester, New York", "locations": [ { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01406873" }, { "nct_id": "NCT02867358", "title": "A Clinical Trial of KT07 Capsule in the U.S.A", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "KT07 Capsule", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Yiling Pharmaceutical Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 391, "start_date": "2016-09", "completion_date": "2020-07-31", "has_results": false, "last_update_posted_date": "2020-08-31", "last_synced_at": "2026-11-04T18:19:48.511Z", "location_count": 81, "location_summary": "Birmingham, Alabama • Pelham, Alabama • Tolleson, Arizona + 66 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Pelham", "state": "Alabama" }, { "city": "Tolleson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02867358" }, { "nct_id": "NCT06132178", "title": "Psilocybin rTMS for Treatment Resistant Depression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Treatment Resistant Depression", "MDD", "Major Depressive Disorder", "Recurrent Depression", "Depression" ], "interventions": [ { "name": "Psilocybin", "type": "DRUG" }, { "name": "Accelerated intermittent theta burst (aiTBS) rTMS treatment", "type": "DEVICE" }, { "name": "Low-dose psilocybin", "type": "DRUG" }, { "name": "Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "University of Texas at Austin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "22 Years to 65 Years" }, "enrollment_count": 100, "start_date": "2025-01-10", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-11-04T18:19:48.511Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06132178" }, { "nct_id": "NCT03512171", "title": "Decision Making Study in Young and Middle-Aged Adults: Part II", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adults" ], "interventions": [ { "name": "Dextroamphetamine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "[18F]Fallypride", "type": "DIAGNOSTIC_TEST" }, { "name": "[18F]-FE-PE2I", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Vanderbilt University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "20 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "20 Years to 65 Years" }, "enrollment_count": 65, "start_date": "2016-03-31", "completion_date": "2018-05-15", "has_results": false, "last_update_posted_date": "2019-06-27", "last_synced_at": "2026-11-04T18:19:48.511Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03512171" }, { "nct_id": "NCT03059563", "title": "Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Dopamine D2/3 Receptor Availability", "Cognitive Function", "Methamphetamine Abuse" ], "interventions": [ { "name": "Varenicline", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 62, "start_date": "2018-01-11", "completion_date": "2023-09-28", "has_results": false, "last_update_posted_date": "2024-05-08", "last_synced_at": "2026-11-04T18:19:48.511Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03059563" } ] }